TLX

Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO® Agreement provides Profound with increased access to urologists via a strong strategic partner and creates a framework to further advance clinical evidence-based patient selection and optimization of patient treatment plans TORONTO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures, is pleased to announce entering into a co-education

First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability.Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer).Pixclara addresses a significant unmet need helping physicians differentiate recurrent or progressive glioma from treatment-related change in adult and pediatric patients 1 month of age and older. MELBOURNE, Australia and INDIANAPOLIS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that the first patients in the United States (U.S.) have been dosed with Pixclara® (floretyrosine F 18 or 18F-FET), its FDA-appr

6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

Transformational merger reinforces Telix’s long-term growth strategy as a vertically integrated radiopharmaceutical company with enhanced capabilities across development, isotope production and global manufacturing, underpinned by commercial excellence and the industry’s most extensive therapeutic pipeline.ITM is the world’s leading supplier of therapeutic radioisotopes, with broad capabilities spanning lutetium-177 (177Lu), actinium-225 (225Ac) and terbium-161 (161Tb) production.ITM is the only producer of globally scaled commercial-grade 177Lu and serves as a key supplier for both commercially available and future therapeutic radiopharmaceuticals.ITM’s commercial-scale and profitable isoto

4 - Telix Pharmaceuticals Ltd (0002007191) (Issuer)

6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer).Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related change in adults and pediatric patients.FET-PET imaging is recommended in international clinical practice guidelines, including NCCN Guidelines®.Pixclara expands Telix’s industry-leading Precision Medicine business and reinforces the Company’s leadership in diagnostics and targeted radiopharmaceutical therapies (together, "theranostics"). MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "T

MELBOURNE, Australia and INDIANAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") advises that Dr. Christian Behrenbruch, Managing Director and Group CEO and Kevin Richardson, CEO, Precision Medicine will present at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference and at the H.C. Wainwright 28th Annual Global Investment Conference, both in New York, NY. Presentation details: Morgan Stanley 24th Annual Global Healthcare ConferenceDate: September 14, 2026Time: 9:15 a.m. EDT (11:15 p.m. AEST) H.C. Wainwright 28th Annual Global Investment ConferenceDate: September 15, 2026Time: 10:30 a.m. EDT (12:30 a.m. AEST, Sep 16)

6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients.Telix has positively engaged with the FDA on a New Drug Application (NDA) pathway in the U.S. that would support new product reimbursement and broaden access to 68Ga-PSMA-PET imaging across a significantly larger patient population.BiPASS is designed to evaluate the diagnostic performance of 68Ga-PSMA-11 PET combined with MRI for the detection of prostate cancer prior to biopsy. MELBOURNE, Australia and INDIANAPOLIS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announced completion of p

6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

David Gill appointed Chair of the Telix Board, effective immediately.Mr. Gill joined Telix as a Non-Executive Director in May 2026, with the intention that he would become Chair.Dr. Mark Nelson will continue to serve on the Board as a Non-Executive Director, having served as interim Chair. MELBOURNE, Australia and INDIANAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix" or the "Company") today announces that David Gill has been appointed Chair of the Board, effective immediately. Mr. Gill joined Telix as a Non-Executive Director in May 2026 as part of the Company’s Board expansion and succession planning1, with the intention that he wo

6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, ", Telix", ) today announces its financial results for the period ended June 30, 2026. H1 2026 key results Group performance1: Double-digit revenue growth and gross margin improvement Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial performance, a favorable product mix and operational efficiencies.Adjusted EBITDA3 of US$52 mil

MELBOURNE, Australia and INDIANAPOLIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City. Institutional investors and analysts are invited to register to attend the in-person session, which will feature a comprehensive overview of Telix's therapeutic and precision medicine pipeline, as well as key scientific, clinical and strategic developments across the portfolio. Members of the Telix leadership team will present at the event, including Managing Director and Group CEO, Dr. Christian Behre

MELBOURNE, Australia and INDIANAPOLIS, July 31, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today advises that it will release its financial results for the half-year ended June 30, 2026 on Thursday August 20, 2026. An investor webcast and conference call will be held at 9:00 a.m. AEST on Thursday August 20, 2026 (7:00 p.m. EDT Wednesday August 19, 2026). Participants can register for the webcast or teleconference at the following link: https://s1.c-conf.com/diamondpass/10056417-pz2402.html About Telix Pharmaceuticals Limited Telix Pharmaceuticals ((ASX: TLX, NASDAQ:TLX) is a commercial-stage global radiopharmaceutical company, advancing targ

Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer. MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announced publication of results from the ProstACT SELECT study in Cancers, a

6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026). Q2 2026 Highlights1 Group revenue of US$247 million, up 7% quarter-over-quarter (QoQ) and up 21% year-over-year (YoY). Precision Medicine continues to deliver strong growth, revenue of US$202 million, up 9% QoQ and up 30% YoY. Telix expects FY 2026 revenue and other income to be in excess of US$1 billion, with revenue tracking in line with the upper end of FY 2026 guidance of US$950 million to US$970 million plus US$40 million non-refund

First patient dosed in Phase 3 LUTEON1 trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC).LUTEON is the first Phase 3 study of a CAIX2-targeted radiopharmaceutical therapy in ccRCC. MELBOURNE (Australia) and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announced that the first patient has been dosed with TLX250-Tx (lutetium-177 (177Lu) girentuximab tetraxetan) in the LUTEON study, the first radiopharmaceutical therapy to enter Phase 3 development for ccRCC. LUTEON is a randomized, prospective, open label, multi-center study evaluating a CAIX-targeting radionuclide therapy in pat

RBC Capital Mkts downgraded Telix Pharmaceuticals from Outperform to Sector Perform

6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

FDA and Telix align on advancement into Part 2 of the ProstACT Global Phase 3 study in the United States.FDA agrees with the clinical protocol and proposed statistical framework across three standard-of-care combination cohorts.Part 2 (randomized cohort) continues to recruit in jurisdictions where the study has regulatory approval. MELBOURNE, Australia and INDIANAPOLIS, July 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals (ASX: TLX, NASDAQ:TLX, "Telix") today announced the successful outcome of a Type B meeting with the United States (U.S.) Food and Drug Administration (FDA) to review the Part 1 safety and dosimetry data and Part 2 protocol design of the ProstACT Global Phase 3 trial o

MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address these. David N. Cade, MD, Telix Group Chief Medical Officer will provide a clinical update, which will be followed by a fireside chat with Nelleke Tolboom, MD, Nuclear Medicine physician and academic faculty member at UMC Utrecht (Netherlands) and Josef Pichler, MD, Head of the Neuro-oncological Center at Kepler University Hospital Linz (Austria). The presentation will be followed by Q&A with